Abstract: The present invention relates to compounds of formula (Ib), wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (Ib), wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: This application provides a data transmission apparatus and a data transmission method. The data transmission apparatus in this application includes: a first connection unit and a control unit, where the first connection unit is a connector plug or a connector socket; and the control unit is configured to: if determining that the first connection unit is in a forward insertion state, control a first data pin pair of the first connection unit to be in a first communication mode, and control a second data pin pair of the first connection unit to be in a second communication mode.

Abstract: An apparatus with a forward-reverse insertion interface and a detection method are provided, and relate to the field of communication technologies, to improve transmission efficiency of an auxiliary channel. The forward-reverse insertion interface of the apparatus includes: a first auxiliary channel (CH1), including a first switch selection circuit (SW1) coupled to a first node (A); a second auxiliary channel (CH2), including a second switch selection circuit (SW2) coupled to a second node (B), where the second switch selection circuit (SW2) and the first switch selection circuit (SW1) are structurally asymmetrical; and a control circuit (CTRL), configured to control switching of the first switch selection circuit (SW1) to change an electrical parameter of the first node (A), and control switching of the second switch selection circuit (SW2) to change an electrical parameter of the second node (B).

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention provides a knowledge graph construction method and device. The method includes: obtaining structured data, where the structured data includes a first entity name of a first entity and attribute information corresponding to the first entity name, and the attribute information includes a first attribute and a first attribute value; performing, based on measurement of a similarity between the first entity and a second entity in a knowledge graph, entity alignment processing on the first entity, where the measurement of the similarity includes at least one of the following types: measurement of a character similarity, measurement of a structure similarity of a classification tree on which an entity is located, and measurement of an attribute similarity; and importing the structured data into the knowledge graph according to an entity alignment processing result. Embodiments may ensure correctness of data in the knowledge graph.

Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds act as antagonists of the toll-like receptors TLR7, TLR8 and/or TLR9 and are thus useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R3, Y and A are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: A method and a device for controlling a remotely controlled mobile platform and a readable storage medium are provided. The method includes: displaying at least one function icon and at least one control icon, where the function icon represents a control program for implementing a preset function, and the control icon is used to control a control terminal and/or a remotely controlled mobile platform to execute the control program; generating, based on a selection operation of a user on the function icon, the control program associated with the selected function icon; and controlling, based on an operation of the user on the control icon, the control terminal and/or the remotely controlled mobile platform to execute the control program.

Abstract: The present invention relates to compounds of formula (I), wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: An image-recognition-based control method includes calling an imaging device of a shooting device to collect an environment image of an environment where the shooting device is currently located; calling a preset human-body-feature-part detection model to perform image area identification on the environment image to provide an identification result; and prohibiting a shooting member of the shooting device from shooing, in response to the identification result indicating that the environment image contains a target image area including a preset human-body-feature-part.